Patients undergoing elective open heart surgery Nefopam, cardiac surgery, opioid sparing effect,
Conditions
Interventions
Patient in Nefopam group will receive Nefopam 20 mg in normal saline solution 100 ml intravenously during chest closure and continue with Nefopam 80 mg in normal saline solution 250 ml intravenously i
Experimental Drug,Placebo Comparator Drug
Sponsors
Siriraj Research Development Fund, Faculty of Medicine, Siriraj Hospital,Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: BMI less than 35 kg/m2 Undergoing elective open heart surgery e.g. CABGs, valve surgery, septal defect surgery Understand and be able to use IV-PCA independently
Exclusion criteria
Exclusion criteria: Emergency surgery Redo-surgery Impaired left ventricular systolic function (LV EF) < 40% Possess any contraindication to nero-am e.g. seizures, MAOI use, glaucoma Creatinine clearance < 40 ml/min Allergic to neropam History of chronic opioid use or any history of drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fentanyl consumption 48 hours Total dose(mcg) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first analgesia The first time to use IV PCA minutes,Pain score 3, 6, 12, 24, 48 hours Visual analog scale,Time to extubation Extubation Hours,ICU length of stay ICU discharge hours,Side effects: Nausea, Tachycardia, sweating, dizziness, hypoventilation 48 hours yes or no ,Cost effectiveness Discharge Total cost, patient's satisfaction with analgesia | — |
Countries
Thailand
Contacts
Public ContactKamheang Vacharaksa
Siriraj Hospital
Outcome results
None listed